QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)

MoonLake Immunotherapeutics (MLTX) Stock Forecast, Price & News

$29.18
+1.03 (+3.66%)
(As of 06/8/2023 ET)
Compare
Today's Range
$27.35
$29.18
50-Day Range
$19.01
$29.18
52-Week Range
$4.48
$30.30
Volume
385,419 shs
Average Volume
290,043 shs
Market Capitalization
$1.54 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.29

MoonLake Immunotherapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
13.3% Downside
$25.29 Price Target
Short Interest
Bearish
13.55% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$11.60 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.00) to ($1.40) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.02 out of 5 stars

Medical Sector

927th out of 981 stocks

Pharmaceutical Preparations Industry

453rd out of 475 stocks


MLTX stock logo

About MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Receive MLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

MLTX Stock News Headlines

MLTX - MoonLake Immunotherapeutics
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 3%
[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
MoonLake Immunotherapeutics (MLTX) Gets a Buy from H.C. Wainwright
See More Headlines

MLTX Price History

MLTX Company Calendar

Last Earnings
3/20/2023
Today
6/08/2023
Next Earnings (Estimated)
8/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MLTX
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.29
High Stock Price Forecast
$36.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
-13.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
11 Analysts

Profitability

Net Income
$-49,970,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.30 per share

Miscellaneous

Free Float
44,654,000
Market Cap
$1.54 billion
Optionable
Not Optionable
Beta
0.93

Key Executives

  • Dr. Jorge Santos da Silva (Age 45)
    Co-Founder, CEO & Director
    Comp: $460.29k
  • Dr. Kristian Reich (Age 57)
    Co-Founder & Chief Scientific Officer
    Comp: $489.9k
  • Mr. Matthias Bodenstedt (Age 35)
    Chief Financial Officer
    Comp: $324.91k
  • Mr. Oliver Daltrop
    Chief Technical Officer
  • Nicolas Mosimann
    Gen. Counsel
  • Annett Zippel
    Director of People & Culture
  • Ms. Nuala Brennan
    Chief Clinical Devel. Officer













MLTX Stock - Frequently Asked Questions

Should I buy or sell MoonLake Immunotherapeutics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MoonLake Immunotherapeutics in the last year. There are currently 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MLTX shares.
View MLTX analyst ratings
or view top-rated stocks.

What is MoonLake Immunotherapeutics' stock price forecast for 2023?

11 Wall Street analysts have issued twelve-month price objectives for MoonLake Immunotherapeutics' stock. Their MLTX share price forecasts range from $16.00 to $36.00. On average, they predict the company's share price to reach $25.29 in the next twelve months. This suggests that the stock has a possible downside of 13.3%.
View analysts price targets for MLTX
or view top-rated stocks among Wall Street analysts.

How have MLTX shares performed in 2023?

MoonLake Immunotherapeutics' stock was trading at $10.50 on January 1st, 2023. Since then, MLTX stock has increased by 177.9% and is now trading at $29.18.
View the best growth stocks for 2023 here
.

Are investors shorting MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 4,320,000 shares, an increase of 30.1% from the April 30th total of 3,320,000 shares. Based on an average daily volume of 355,000 shares, the days-to-cover ratio is currently 12.2 days. Currently, 13.6% of the company's stock are short sold.
View MoonLake Immunotherapeutics' Short Interest
.

When is MoonLake Immunotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our MLTX earnings forecast
.

How were MoonLake Immunotherapeutics' earnings last quarter?

MoonLake Immunotherapeutics (NASDAQ:MLTX) released its quarterly earnings data on Monday, March, 20th. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.02.

What ETFs hold MoonLake Immunotherapeutics' stock?

ETFs with the largest weight of MoonLake Immunotherapeutics (NASDAQ:MLTX) stock in their portfolio include BlackRock Future Health ETF (BMED) and First Trust IPOX Europe Equity Opportunities ETF (FPXE).

What is MoonLake Immunotherapeutics' stock symbol?

MoonLake Immunotherapeutics trades on the NASDAQ under the ticker symbol "MLTX."

Who are MoonLake Immunotherapeutics' major shareholders?

MoonLake Immunotherapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (1.58%), Federated Hermes Inc. (1.53%), FMR LLC (0.90%), JPMorgan Chase & Co. (0.58%), AXA S.A. (0.57%) and Great Point Partners LLC (0.53%).
View institutional ownership trends
.

How do I buy shares of MoonLake Immunotherapeutics?

Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MoonLake Immunotherapeutics' stock price today?

One share of MLTX stock can currently be purchased for approximately $29.18.

How much money does MoonLake Immunotherapeutics make?

MoonLake Immunotherapeutics (NASDAQ:MLTX) has a market capitalization of $1.54 billion. The company earns $-49,970,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis.

How can I contact MoonLake Immunotherapeutics?

The official website for the company is www.moonlaketx.com. The company can be reached via phone at 41-41-510-8022 or via email at ir@moonlaketx.com.

This page (NASDAQ:MLTX) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -